Company Stock Price of Catabasis Pharmaceuticals, Inc. (CATB) Decreases -24.02%

Catabasis Pharmaceuticals, Inc. s trend and data analysis indicates that the stock price has dropped -58.67% in the past 12 Weeks but analyzing the 6 month chart of the stock, the price of the stock has managed to drop negative and it has dropped down to -74.84% . Looking at the past 52 week period, the stock price is down -74.12% . Relative price strength is a important factor used by wealth management firms while investing in stocks since the indicator compares the stock performance with the overall market. The relative price strength of Catabasis Pharmaceuticals, Inc. has a negative value of -8.39 compared to overall market performance.Catabasis Pharmaceuticals, Inc. is having a Relative Strength Index of 44.85 which indicates the stock is not yet over sold or over bought based on the technical indicators.

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) has tumbled 24.02% during the past week, however, the bigger picture is still very bullish; the stocks have advanced and posted positive gains of 24% in the last four weeks. The stocks have underperformed the S&P 500 by 24.2% during the past week but Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) it has outperformed the index in 4 weeks by 22.59%.

For the current week, the company shares have a recommendation consensus of Buy. Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) stock ended Friday session in the red zone in a volatile trading. The stock closed down 0.15 points or 8.82% at $1.55 with 1,418,712 shares getting traded. Post opening the session at $1.75, the shares hit an intraday low of $1.55 and an intraday high of $1.75 and the price was in this range throughout the day. The company has a market cap of $29 million and the number of outstanding shares has been calculated to be 18,652,303 shares. The 52-week high of Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) is $7.89 and the 52-week low is $1.08.

Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Catabasis Pharmaceuticals Inc was Downgraded by Citigroup to Neutral on Feb 2, 2017. Catabasis Pharmaceuticals Inc was Initiated by H.C. Wainwright on Dec 22, 2016 to Buy, Price Target of the shares are set at $14.

Company has reported several Insider transactions to the SEC, on Jun 30, 2015, Jean George (director) purchased 258,776 shares at 12.00 per share price.On Jun 30, 2015, Nicholas Galakatos (director 10% owner) purchased 376,695 shares at 12.00 per share price.On Jun 30, 2015, Ventures, Inc. Medimmune (10% owner) purchased 223,439 shares at 12.00 per share price.

Catabasis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of therapeutics for treatment of inflammatory, immunological and metabolic diseases. Its product development pipeline includes CAT-1004, CAT-2000 series including CAT-2054 and CAT-2003, CAT-4001 as well as various programs which are in different clinical-stage. Catabasis Pharmaceuticals, Inc. is based in Cambridge, Massachusetts.

Catabasis

Leave a Reply

Your email address will not be published. Required fields are marked *